Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sprint Bioscience ABFRA:5JA1 +3.00%27 Cyclically Adjusted PB Ratio is 1.83 as of Sep. 03, 2026, which is 205% above its 10-year median of 0.60. GuruFocus rates FRA:5JA1 with a GF Score™ of 27/100. The stock has 1 warning sign investors should review. Among 684 Biotechnology companies, Sprint Bioscience AB ranks worse than 50.73% on this metric.
The historical rank and industry rank for Sprint Bioscience AB's Cyclically Adjusted PB Ratio or its related term are showing as below:
FRA:5JA1'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.21 Med: 0.6 Max: 2.38
Current: 1.7
During the past years, Sprint Bioscience AB's highest Cyclically Adjusted PB Ratio was 2.38. The lowest was 0.21. And the median was 0.60.
FRA:5JA1's Cyclically Adjusted PB Ratio is ranked worse than 50.73% of 684
companies
in the Biotechnology industry
Industry Median: 1.615
vs FRA:5JA1: 1.70
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Sprint Bioscience AB's adjusted book value per share data for the three months ended in Mar. 2026 was €0.094. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.15 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Sprint Bioscience AB (FRA:5JA1) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Sprint Bioscience AB Cyclically Adjusted PB Ratio Related Terms
Sprint Bioscience AB Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Sprint Bioscience AB's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sprint Bioscience AB Cyclically Adjusted PB Ratio Chart
FRA:5JA1 vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Sprint Bioscience AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sprint Bioscience AB Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Sprint Bioscience AB's Cyclically Adjusted PB Ratio falls into.
Sprint Bioscience AB Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 1.83 mean?
Sprint Bioscience AB (FRA:5JA1) has a Cyclically Adjusted PB Ratio of 1.83 as of Sep. 03, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Sprint Bioscience AB and its competitors. This is 205% above median its historical median of 0.60. Over the past decade, Sprint Bioscience AB's Cyclically Adjusted PB Ratio has ranged from 0.21 to 2.38. According to the industry distribution chart, Sprint Bioscience AB ranks #347 out of 684 companies in the Biotechnology industry, placing it in the top 50.7%.
Is Sprint Bioscience AB's Cyclically Adjusted PB Ratio too high?
Sprint Bioscience AB's current Cyclically Adjusted PB Ratio of 1.83 is 205% above median its 10-year median of 0.60. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 2.38. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.62. Sprint Bioscience AB's value of 1.83 is 13.3% above this industry median. Based on the distribution chart, Sprint Bioscience AB ranks #347 out of 684 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sprint Bioscience AB has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's Cyclically Adjusted PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sprint Bioscience AB ranks #347 out of 684 companies for Cyclically Adjusted PB Ratio. This places Sprint Bioscience AB in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.62. Sprint Bioscience AB's value of 1.83 is 13.3% above this benchmark. Historically, Sprint Bioscience AB's own Cyclically Adjusted PB Ratio has ranged from 0.21 to 2.38 over the past decade. While the company's 10-year median is 0.60 vs. the industry median of 1.62, Sprint Bioscience AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.62, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sprint Bioscience AB's current Cyclically Adjusted PB Ratio of 1.83 is 13.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Sprint Bioscience AB and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sprint Bioscience AB's current Cyclically Adjusted PB Ratio is 1.83, which is 205% above median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Sprint Bioscience AB (FRA:5JA1) has a current Cyclically Adjusted PB Ratio of 1.83. The current Cyclically Adjusted PB Ratio is 1.83, which is 205% above median its 10-year median of 0.60 and 13.3% above the Biotechnology industry median of 1.62. Sprint Bioscience AB's overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Sprint Bioscience AB (FRA:5JA1), the current Cyclically Adjusted PB Ratio is 1.83 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
27GF Score
Get the complete analysis for FRA:5JA1
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5JA1 has been successfully added to your 
